Early in 2001, the effect of cetuximab was investigated in squamous cell carcinoma in vivo, which also enhanced the efficacy of radiotherapy.253,254 Xenograft models revealed that EGFR inhibitor monotherapy led to partial and transient tumor regression. This evidence concerns the gene EGFR and neoplasm.